Insulin resistance
Drug research and approvals for insulin resistance: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 387 studies of insulin resistance are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 387
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Repurposing Insulin With Intranasal Administration to Improve Function After Mild Traumatic Brain InjuryNCT07935278 · Phase 2 · HealthPartners Institute · starts Nov 1, 2026
- Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 DiabetesNCT07928661 · Phase 2 · Universitas Sriwijaya · starts Jul 29, 2026
- Fulvic Acid Supplementation and Metabolic SyndromeNCT07927283 · Not applicable · Arizona State University · starts Nov 6, 2026
- Asprosin and miRNA Expression in Young Women With Metabolic SyndromeNCT07917364 · Not reported · University of Applied Sciences in Nowy Targ · starts Nov 1, 2026
- Effect of Resistance Exercises on Serum IGF-1 Levels in Knee OsteoarthritisNCT07890155 · Not applicable · Sisli Hamidiye Etfal Training and Research Hospital · starts Jun 1, 2026
- RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGMNCT07861191 · Not reported · National University Health System, Singapore · starts Jul 27, 2026
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07854782 · Phase 3 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Effects of Pistachios on Postprandial Metabolic Responses in Adults With Overweight or ObesityNCT07853898 · Not applicable · St. Louis University · starts Oct 1, 2026
- Effects of Hourly Stair-Climbing Exercise Snacks on Metabolic and Vascular Health in Adults With PrediabetesNCT07847684 · Not applicable · St. Louis University · starts Oct 1, 2026
Phase 3 10
- Insulin humanInsulin receptor agonist
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- Insulin porkInsulin receptor agonist
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- TadalafilPhosphodiesterase 5A inhibitor
- Omega-3-ACID ethyl esters
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- Thiazolidinedione
Phase 2 7
- MetreleptinLeptin receptor agonist
- ErgocalciferolVitamin D receptor agonist
- Sevelamer
- EritoranToll-like receptor 4/MD-2 antagonist
- Triflusal
- Maltodextrin
- Resveratrol
Phase 1 or earlier 12 of 19
- Salsalate
- ElvitegravirHuman immunodeficiency virus type 1 integrase inhibitor
- CobicistatCytochrome P450 3A inhibitor
- Bezisterim
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- Tenofovir alafenamideHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- RilpivirineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- TrimethaphanNeuronal acetylcholine receptor; alpha3/beta4 antagonist
- LopinavirHuman immunodeficiency virus type 1 protease inhibitor
- DarunavirHuman immunodeficiency virus type 1 protease inhibitor
How its trials ended
1,644 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 331 whose ending is known, 45% met their primary endpoint, 11% missed it and 44% stopped early.
- Completed, result not reported90755%
- Ongoing22314%
- Status unknown18311%
- Met its primary endpoint1499%
- Stopped: other or unclear905%
- Missed its primary endpoint362%
- Stopped: enrollment or feasibility312%
- Stopped: funding111%
- Stopped: lack of efficacy7<1%
- Stopped: sponsor or business decision5<1%
- Stopped: safety2<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Dec 9, 2003 | rhIGF-I/rhIGFBP-3Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, type B syndrome) | Insmed, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA